Chicago, IL – June 3, 2026 – The American Society of Clinical Oncology (ASCO) 2026 annual meeting, held from May 29 to June 2, 2026, served as a crucial platform for unveiling cutting-edge research in metastatic colorectal cancer (mCRC). Among the numerous presentations and abstracts, two studies garnered significant attention from experts: Cardiff Oncology’s Phase II CRDF-004 trial investigating onvansertib in RAS-mutated mCRC, and Shanghai Kechow Pharma’s Phase III trial of Kolupin in BRAF V600E-mutant mCRC. These findings offer glimmers of hope for patient populations with historically challenging-to-treat mutations, while simultaneously underscoring the persistent unmet needs within the mCRC landscape.
GlobalData Healthcare analysts have delved into the implications of these emerging therapies, examining their potential impact on patient care and the evolving treatment paradigms for mCRC.
Unmet Needs in mCRC: A Persistent Challenge
Metastatic colorectal cancer remains a formidable disease, characterized by complex genetic mutations that dictate treatment response and patient outcomes. For decades, the standard of care for many mCRC patients has relied on chemotherapy regimens, often in combination with targeted agents. However, significant subsets of patients harbor specific mutations, such as those in the RAS (KRAS and NRAS) and BRAF genes, which confer resistance to certain therapies and lead to poorer prognoses.
RAS mutations, found in approximately 45% of mCRC patients, are particularly notorious for their association with resistance to anti-epidermal growth factor receptor (EGFR) therapies. While targeted therapies for the less common KRAS G12C mutation have emerged, the broader spectrum of RAS-mutated mCRC presents a significant therapeutic hurdle. Similarly, BRAF V600E mutations, while less prevalent, also necessitate specialized treatment approaches. The lack of substantial progress in extending survival for these patient groups has amplified the urgency for novel therapeutic strategies.
Cardiff Oncology’s Onvansertib: A Potential Breakthrough for RAS-Mutated mCRC
Harnessing PLK1 Inhibition in a Difficult-to-Treat Population
One of the most anticipated presentations at ASCO 2026 was from Cardiff Oncology, detailing the progress of their Phase II randomized CRDF-004 trial (NCT06106308). This study focused on patients with RAS-mutated unresectable mCRC receiving first-line standard of care (SoC) chemotherapy, either FOLFIRI (leucovorin, fluorouracil, irinotecan) or FOLFOX (leucovorin, fluorouracil, oxaliplatin), both in combination with bevacizumab. The trial’s innovation lay in evaluating the addition of onvansertib, an oral small molecule polo-like-kinase 1 (PLK1) inhibitor, at two dose levels (20mg and 30mg) to this established backbone, comparing it against SoC alone.
The primary endpoint of the CRDF-004 trial was objective response rate (ORR), with crucial secondary endpoints including progression-free survival (PFS), duration of response (DoR), and safety. While the data is still maturing, the presented results have ignited considerable optimism, suggesting the trial is on track to meet its primary endpoints. Specifically, the combination of onvansertib with FOLFIRI and bevacizumab demonstrated promising anti-tumor activity and an acceptable safety profile.
Promising Efficacy Signals
The trial enrolled 110 patients, who were randomized across six arms: bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX, each with or without onvansertib at 20mg or 30mg. Baseline characteristics were reported to be largely balanced across these arms, a critical factor for robust data interpretation.
The most compelling results emerged from the onvansertib 30mg plus FOLFIRI plus bevacizumab arm, which achieved a remarkable confirmed ORR of 72.2%. This significantly outpaced the FOLFIRI plus bevacizumab control arm, which reported an ORR of 42.1%, and the FOLFOX plus bevacizumab arm at 44.4%. These figures suggest a substantial improvement in tumor shrinkage when onvansertib is integrated into the FOLFIRI-bevacizumab regimen.
Beyond response rates, the impact on progression-free survival (PFS) also appeared highly encouraging. When comparing onvansertib (at both 20mg and 30mg doses) in combination with FOLFIRI-bevacizumab against SoC, the median PFS in the experimental arms was not reached. In contrast, the FOLFIRI plus bevacizumab control arm reported a median PFS of 10.97 months, as assessed by investigator. This translated to a hazard ratio (HR) of 0.53, indicating a substantial reduction in the risk of disease progression or death.
Safety Profile and Future Directions
The reported safety profile of onvansertib in combination therapy was described as manageable. Neutropenia emerged as the most common Grade 3 or higher adverse event (AE), a known toxicity associated with some chemotherapy regimens and targeted agents.
Despite the encouraging signals, it is important to acknowledge the limitations of the current data. The per-arm sample sizes, while sufficient for a Phase II study, remain relatively small, necessitating confirmatory evidence from larger trials. Cardiff Oncology has already recognized this and has announced plans for a Phase III evaluation of onvansertib at the 30mg dose in combination with FOLFIRI and bevacizumab, a critical step towards potential regulatory approval.
Addressing a Critical Unmet Need
The significance of these findings cannot be overstated. The treatment of RAS-mutant mCRC represents one of the most substantial unmet needs within the broader indication. As highlighted by GlobalData’s "Colorectal Cancer: Eight-Market Drug Forecast and Market Analysis 2021–2032" report, KRAS and NRAS mutations collectively affect nearly half of all mCRC patients. These mutations historically render patients unresponsive to anti-EGFR therapies, a cornerstone of mCRC treatment for many years. The standard first and second-line treatment of bevacizumab plus chemotherapy has seen minimal evolution over the past two decades, with median PFS typically ranging from nine to eleven months. This stagnation underscores the critical demand for more effective therapeutic strategies that can overcome resistance mechanisms driven by RAS mutations.
Onvansertib’s potential to offer a mutation-agnostic approach, applicable across the full spectrum of RAS-mutant disease regardless of the specific mutation subtype, positions it as a uniquely valuable asset in development. Furthermore, its investigation extends beyond CRC to a broad range of malignancies, including pancreatic cancer, chronic myelomonocytic leukemia, breast cancer, small-cell lung cancer, and skin cancer. This broad applicability fuels significant commercial expectations, with GlobalData’s analyst consensus forecast projecting onvansertib to achieve over $1 billion in sales by 2032.
Shanghai Kechow Pharma’s Kolupin Combo: Navigating the BRAF V600E Landscape
Targeting BRAF V600E Mutations in Pre-Treated Patients
Another significant area of focus at ASCO 2026 was the treatment of BRAF V600E-mutant mCRC. Shanghai Kechow Pharma presented results from their sponsored Phase III, randomized, open-label trial (NCT06008119). This trial enrolled patients with BRAF V600E-mutant mCRC who had previously received at least one line of systemic therapy.
The study compared a novel combination of Kolupin (tunlametinib), Shanghai Kechow Pharma’s oral mitogen-activated extracellular signal-regulated kinase (MEK1/2) inhibitor, in combination with Zelboraf (vemurafenib), Roche’s BRAF inhibitor, against the investigator’s choice of therapy. The primary endpoint was PFS, with overall survival (OS), ORR, disease control rate (DCR), and safety serving as key secondary endpoints.
Positive Primary Endpoint Achievement
The tunlametinib plus vemurafenib combination demonstrated a statistically significant improvement in PFS compared to the control arm. The median PFS in the experimental arm was 4.2 months, a notable increase from the 1.5 months observed in the control arm, resulting in an HR of 0.342. This indicates a substantial reduction in the risk of disease progression or death for patients receiving the Kolupin and Zelboraf combination.
Further reinforcing the efficacy of the combination, confirmed ORR stood at 26.7% in the experimental arm versus 3.7% in the control arm. The disease control rate (DCR) also showed a marked difference, with 85.7% of patients in the Kolupin-Zelboraf arm achieving disease control compared to 40.4% in the control arm.
Challenges and Contextualizing the Results
While the primary endpoint was met, the interpretation of these results is nuanced by several factors. Firstly, the overall survival (OS) data remains immature, meaning a full picture of the long-term benefits is not yet available. Secondly, baseline characteristics were not perfectly balanced between the arms. Notably, a higher proportion of patients in the experimental arm (61.9%) had three or more metastatic sites compared to the control arm (46.2%), a factor that could potentially influence outcomes.
Crucially, the tunlametinib plus vemurafenib trial was initiated prior to the availability of results from the pivotal BREAKWATER trial. Patients were BRAF inhibitor-naïve at the time of enrollment, and doublet or triplet chemotherapy was utilized as first-line treatment. This timing raises questions about how these findings fit into the rapidly evolving treatment landscape for BRAF V600E-mutant mCRC.
The Shifting Treatment Paradigm for BRAF V600E mCRC
The landscape for BRAF V600E-mutant mCRC has been dramatically reshaped by recent advancements. The BREAKWATER trial established a new frontline standard, with Pfizer’s Braftovi (encorafenib) in combination with cetuximab and chemotherapy receiving US Food and Drug Administration (FDA) approval. This regimen demonstrated a doubling of OS in BRAF V600E-mutant mCRC, with median PFS of 12.8 months and median OS of 30.3 months, representing a landmark achievement in the field.
In the previously treated setting, the BEACON CRC trial had previously set a benchmark with Braftovi plus cetuximab, yielding a median PFS of 4.2 months and median OS of 8.4 months. This raises a critical question: could replacing vemurafenib with encorafenib in the Kolupin combination lead to meaningfully improved outcomes?
The VIC regimen (vemurafenib, irinotecan, and cetuximab/panitumumab) was an early BRAF V600E-targeted combination to gain recommendation from the US National Comprehensive Cancer Network (NCCN). However, it has since been removed from guidelines in favor of newer BRAF-targeted regimens with more mature efficacy data and better tolerability.
The BREAKWATER trial has significantly reduced the pool of BRAF inhibitor-naïve patients available for later-line treatment, the very population studied in the Kolupin trial. Furthermore, the post-encorafenib retreatment space appears to be consolidating around encorafenib-cetuximab rechallenge strategies, rather than alternative BRAF inhibitor combinations. This trend further constrains the potential niche for tunlametinib plus vemurafenib.
Geographic Considerations and Regulatory Hurdles
An additional layer of complexity arises from the geographic distribution of the study population. Over 50% of enrolled patients had left-sided tumors, despite BRAF V600E-mutant colorectal cancer being predominantly right-sided. The presenter attributed this to geographic differences within the Chinese population. Given that the trial was conducted exclusively in China, potential differences in tumor biology may limit the applicability of these findings to Western patients. Regulatory agencies such as the FDA and the European Medicines Agency (EMA) may require additional bridging studies before granting approval, adding further uncertainty to the global adoption of this therapy.
Conclusion: A Dual Narrative of Progress and Persistent Challenges
The ASCO 2026 meeting has painted a compelling picture of progress in the fight against metastatic colorectal cancer. The promising results for onvansertib in RAS-mutated mCRC offer a much-needed beacon of hope for a significant patient population historically underserved by treatment advancements. The drug’s potential for broad applicability across RAS mutations and its promising early efficacy data position it as a key contender in the future mCRC treatment landscape.
Conversely, the Kolupin trial, while meeting its primary endpoint, highlights the dynamic and competitive nature of mCRC treatment development, particularly in the BRAF V600E-mutant space. The rapid evolution of treatment standards, driven by groundbreaking trials like BREAKWATER, necessitates careful contextualization of new data and raises questions about the long-term viability of certain therapeutic combinations.
As the field continues to advance, the focus remains on identifying and validating therapies that can overcome specific genetic drivers of resistance, improve patient survival, and enhance quality of life. The discussions and data presented at ASCO 2026 underscore the ongoing commitment of researchers and pharmaceutical companies to address the complex and evolving challenges of metastatic colorectal cancer. The journey towards more effective and personalized treatments continues, fueled by innovation and a deep understanding of the molecular intricacies of this disease.
About the Author
